Therma Bright Inc V.THRM

Alternate Symbol(s): TBRIF

Healthcare Medical Devices

Therma Bright Inc. is a Canada-based company, which is a developer and partner in a range of diagnostic and medical device technologies. It focuses on providing consumers and medical professionals with solutions that address medical and healthcare challenges. It is involved in developing, acquiring, manufacturing, and marketing proprietary healthcare and medical devices for the consumer and institutional marketplace. Its product offerings include Covid-19 diagnostic test product line, such as AcuVid COVID-19 Rapid Antigen Saliva Test and AcuVid COVID-19 Rapid Antibody Test; Sores & Bite Inflammation Therapy product line, such as InterceptCS Cold Sore Prevention System and TherOZap, and Muscle Pain & Blood Circulation Health Therapy product line, such as Venowave, which is a circulation booster designed to improve circulation in the lower extremities. Its products include Benepod, Inretio, AI4LYF, Invixa and Instatin, and others.

TSXV:THRM - Post by User

Therma Bright Inc > Torion

<< Previous

Bullboard Posts

Next >>

Comment by Whydunniton Nov 07, 2020 2:33am

92 Views

Post# 31856860

RE:RE:RE:RE:RE:RE:RE:RE:Torion

CryptoCap wrote:

Whydunnit wrote:

I kinda agree with you. Therma owned 100% and paid Orph for their help, including shares which would have grown in value with the success of covisafe. Can't remember the exact number of shares that went to Orph before, somewhere around a couple of million. Now, after the peptides have been identified, he gives 50% of the device to Orph, roughly the earning equivalent of 98 million THRM shares. That doesn't add up to me as good deal making. Since Orph has already been paid for their work, shouldn't they have to be paying for that 50% stake going forward? Okay, they'll still be involved with some work going forward, but a few million shares at a time would seem to more equitable. What did they pay, if anything, for the earning equivalent of 98 million shares? If they're going to be involved further, is that worth 50% of the device profits on top of what they'd already been paid? Lots to be explained still but at this point it looks like THRM gave away too much. IMO of course.

WRONG AGAIN....the codevelopment was always 50/50 but THRM has to provide capital for their end of the deal...oprheus provided the initial biological candidates and obviously the expertse to get this off the ground...THRM did not give up anything...this was always 50/50